Cyfuse Biomedical K.K. (TYO:4892)

Market Cap	7.67B
Revenue (ttm)	68.00M
Net Income (ttm)	-810.00M
Shares Out	8.30M
EPS (ttm)	-99.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,400
Average Volume	125,090
Open	916.00
Previous Close	916.00
Day's Range	916.00 - 939.00
52-Week Range	430.00 - 1,412.00
Beta	1.69
RSI	42.77
Earnings Date	May 15, 2025

About Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was inco...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 21
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4892

Financial Performance

In 2024, Cyfuse Biomedical K.K.'s revenue was 54.00 million, a decrease of -11.48% compared to the previous year's 61.00 million. Losses were -872.00 million, 48.0% more than in 2023.